Compugen Ltd. (NASDAQ:CGEN) announced today positive results from a recently completed in vivo study of CGEN-25007, a novel peptide antagonist of the gp96 protein.

Compugen Ltd. (NASDAQ:CGEN) announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

Compugen Ltd. (NASDAQ:CGEN) announced today the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3).

Compugen Ltd. (NASDAQ:CGEN) announced today that it has signed a collaborative discovery and license agreement with Roche. The collaboration will cover the identification and validation of genetic variations for the prediction of response to drugs used for the treatment of rheumatoid arthritis.

Compugen Ltd. (NASDAQ:CGEN) announced today a collaboration with Mayo Clinic targeted at discovering and validating novel biomarkers for diagnosing the presence of unstable atherosclerotic plaques in coronary artery disease and cerebrovascular disease.